Recombinant Human HDAC6 293 Cell Lysate

• Cat.No.: HDAC6-5603HCL

Specification

• Description: Antigen standard for histone deacetylase 6 (HDAC6) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: HDAC6 histone deacetylase 6 [ Homo sapiens ]
• Official Symbol: HDAC6
• Synonyms: HDAC6; histone deacetylase 6; FLJ16239; HD6; JM21; KIAA0901
• Gene ID: 10013
• mRNA Refseq: NM_006044
• Protein Refseq: NP_006035
• MIM: 300272
• UniProt ID: Q9UBN7
• Chromosome Location: Xp11.23
• Pathway: Cell cycle, organism-specific biosystem; NOTCH1 Intracellular Domain Regulates Transcription, organism-specific biosystem; Signal Transduction, organism-specific biosystem; Signaling by NOTCH, organism-specific biosystem; Signaling by NOTCH1, organism-specific biosystem; Signaling events mediated by HDAC Class I, organism-specific biosystem; Signaling events mediated by HDAC Class II, organism-specific biosystem
• Function: Hsp90 protein binding; NAD-dependent histone deacetylase activity (H3-K14 specific); NAD-dependent histone deacetylase activity (H3-K9 specific); NAD-dependent histone deacetylase activity (H4-K16 specific); actin binding; alpha-tubulin binding; beta-catenin binding; beta-tubulin binding; dynein complex binding; enzyme binding; histone deacetylase activity; histone deacetylase activity (H3-K16 specific); histone deacetylase binding; hydrolase activity; metal ion binding; microtubule binding; microtubule binding; polyubiquitin binding; protein binding; tau protein binding; tubulin deacetylase activity; tubulin deacetylase activity; zinc ion binding

Reviews

06/23/2019

Their expertise and guidance have helped overcome hurdles, ensuring the smooth progress of my research.

12/07/2018

The bands of proteins in Western Blotting experiments were very clear.

09/16/2018

Its purity and consistency have provided me with reliable and reproducible results, ensuring the accuracy of my research findings.

Q&As

Can HDAC6 inhibitors be used in combination with other therapies, and if so, what synergistic effects are expected?

Yes, HDAC6 inhibitors can be combined with other therapies for enhanced efficacy. Synergistic effects may include improved anti-cancer activity or neuroprotection.

Are there any ongoing clinical trials targeting HDAC6, and if so, what are the potential outcomes for patients?

Yes, there are clinical trials exploring HDAC6 inhibitors as potential treatments. Positive outcomes could lead to new therapeutic options for patients.

In what other diseases has HDAC6 been implicated, and how might this knowledge be applied clinically?

HDAC6 is implicated in neurodegenerative diseases and inflammatory disorders. Understanding its role could lead to novel therapeutic approaches for these conditions.

How does HDAC6 influence cellular processes, and why is this relevant in a clinical setting?

HDAC6 regulates cell motility, protein trafficking, and other processes. Understanding these mechanisms is crucial for developing targeted therapies in various diseases.

Are there any known genetic variations in HDAC6, and how might these impact individual responses to treatments in a clinical setting?

Genetic variations in HDAC6 may influence individual responses to treatments. Personalized medicine approaches could consider these variations for better outcomes.